Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL

Clinical Trial ID NCT00655837

PubWeight™ 2.22‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00655837

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol 2015 1.54
2 Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1. Immunotherapy 2015 0.81
Next 100